About us

Trojantec was founded by its President and Chairman, Agamemnon A. Epenetos and its Scientific Director, Dr Christina Kousparou who decided to develop novel drugs in the area of oncology.

Trojantec has a wholly owned UK subsidiary (Trojan Technologies Ltd), which has identified and secured exclusive rights to innovative therapeutics in oncology from Imperial College, London. Its management team has the expertise and experience to design, manage, and execute the clinical development of selected leading candidates right through to product registration.